Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...

The S&P 500 climbed 0.61% on Wednesday (July 9), driven by gains in tech stocks as Nvidia hit a historic milestone and ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company ...

Investing.com -- Italian authorities appointed a special commissioner on Monday to help Novo Nordisk (NYSE:NVO) deliver its planned €2 billion ($2.34 billion) investment in a factory near Rome ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to ...

Novo Nordisk boosts manufacturing capacity for GLP-1 drugs again, unveiling a $4.1 billion fill-and-finish facility in North Carolina.

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant. The new ...